Clinical Trials in Dallas

Showing 3881-3900 of 17,468 trials

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

NCT03878199

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Giving ruxolitinib and CPX-351 may work better in treating patients with secondary acute myeloid leukemia compared to CPX-351 alone.

Essential ThrombocythemiaMyelofibrosisMyeloproliferative Neoplasm+2 more

Ohio State University Comprehensive Cancer Center12 participantsStarted Feb 2019

Columbus, Ohio, United States • Portland, Oregon, United States • Dallas, Texas, United States

Active Not RecruitingPhase 1/2< 1 mile

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

NCT01012817

This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to treatment, or primary peritoneal cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib with chemotherapy may kill more tumor cells.

Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more

National Cancer Institute (NCI)88 participantsStarted Nov 2009

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Sacramento, California, United States +12 more locations

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Find Trials by Condition in Dallas

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

Strong Teens for Healthy Schools Change Club: A Civic Engagement Approach to Improving Physical Activity and Healthy Eating Environments

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Use of Stromal Vascular Fraction in Multiple Sclerosis